Allogeneic Hematopoietic Stem Cell Transplantation Clinical Trial
Official title:
Clinical Study of TBF Regimen in Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Central Nervous System Leukemia
Central nervous system (CNS) leukemia is a poor prognostic factor for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thiotepa can penetrate the blood-brain barrier and has immunosuppressive effects and similar effects to irradiation in allo-HSCT. This project aims to investigate whether the TBF regimen is superior to the traditional modified BuCY2 regimen to improve the long-term survival of the CNS leukemia patients.
Central nervous system (CNS) leukemia is a common extramedullary leukemia and a poor prognostic factor for allogeneic hematopoietic stem cell transplantation (allo-HSCT). There is a blood-brain barrier (BBB) in the CNS. The treatment effect of CNS leukemia is seriously limited by the low penetration of conventional chemotherapy drugs into cerebrospinal fluid. Thiotepa can penetrate the BBB and has immunosuppressive effect and myeloablative effect similar to irradiation in transplantation. Therefore, it is speculated that cestipide has certain advantages as a conditioning regimen in transplantation for CNS leukemia. This project aims to investigate whether the TBF regimen is superior to the traditional modified BuCY2 regimen to improve the long-term survival of the CNS leukemia patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03294824 -
Non Randomized Comparative Study With Control
|
||
Recruiting |
NCT04098653 -
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
|
Phase 2/Phase 3 | |
Recruiting |
NCT03256071 -
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT
|
Phase 2/Phase 3 | |
Terminated |
NCT02653196 -
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
|
Early Phase 1 | |
Terminated |
NCT00429039 -
A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT05084027 -
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
|
Phase 2 | |
Recruiting |
NCT04123392 -
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
|
Phase 2/Phase 3 | |
Recruiting |
NCT05596981 -
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
|
||
Recruiting |
NCT05601895 -
The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance
|
||
Recruiting |
NCT05596968 -
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
|
||
Recruiting |
NCT03357172 -
Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Active, not recruiting |
NCT04995653 -
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
|
Phase 1 | |
Completed |
NCT02250300 -
MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT04372524 -
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
|
||
Recruiting |
NCT03593161 -
Humor Therapy and Distress After Allogeneic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT05379569 -
Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL
|
Phase 4 | |
Not yet recruiting |
NCT03902041 -
The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT
|
||
Completed |
NCT02270346 -
Inspiratory Muscle Training in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
|
N/A | |
Recruiting |
NCT03297528 -
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
|
Phase 2 |